Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP, Chief Financal Officer | September 10, 2026 | September 14, 2026 |
| NUVASIVE INCNUVA · Entity 110002 | Chief Accounting Officer | February 01, 2018 | February 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,828 |
Reported balance
After 2026-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 3,638 · Balance 146,828 F1: On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.
NUVASIVE INC
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,943 |
Last balance in matching sequence
After 2018-02-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-02-01 · Exercise / conversion · Acquired 931 · Balance 8,323 F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 2 · 2018-02-01 · Tax withholding · Disposed 380 · Balance 7,943 F2: Shares withheld by the Issuer to satisfy tax withholding obligations. F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 931 |
Reported balance
After 2018-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-01 · Exercise / conversion · Disposed 931 · Balance 931 F3: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017 and February 1, 2018 and will vest as to 931 shares on February 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards.
F2: Shares withheld by the Issuer to satisfy tax withholding obligations.
F3: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F4: This RSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the RSU award, the award vested as to 932 shares on February 1, 2016, vested as to 931 shares on February 1, 2017 and February 1, 2018 and will vest as to 931 shares on February 1, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:02 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,638 | $83.27 | $302,936.26 |
DisclosureSEC source: 0001093557-26-000173 · wk-form4_1789416164.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,828 F1 · shares: On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. Read SEC document |
| August 22, 2026 Filed Aug 25, 2026 20:14 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 1,451 | $92.34 | $133,985.34 |
DisclosureSEC source: 0001093557-26-000158 · wk-form4_1787688882.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,390 F1 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:39 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 1,451 | $71.90 | $104,326.90 |
DisclosureSEC source: 0001093557-26-000097 · wk-form4_1779914342.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,841 F1 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Included in this number are 89,944 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 18,950 | $68.10 | $1,290,495.00 |
DisclosureSEC source: 0001093557-26-000049 · wk-form4_1773172914.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,292 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 92,794 unvested RSUs, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 261 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 48,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000049 · wk-form4_1773172914.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,242 F1 · shares: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 2,652 | $73.36 | $194,550.72 |
DisclosureSEC source: 0001093557-26-000011 · wk-form4_1770068790.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,207 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 79 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 7,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000011 · wk-form4_1770068790.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,859 F1 · shares: Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,824 | $74.17 | $357,796.08 |
DisclosureSEC source: 0001093557-25-000249 · wk-form4_1757016814.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,657 F1 · shares: On May 27, 2025, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 12,001 | $70.38 | $844,631.58 |
DisclosureSEC source: 0001093557-25-000079 · wk-form4_1741987510.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,481 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,127 | $74.70 | $84,189.49 |
DisclosureSEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 5 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,482 F5 · price: This transaction was executed in multiple trades at prices ranging from $74.61 to $74.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F6 · balance_after: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 252 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,203 | $74.04 | $237,151.40 |
DisclosureSEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 4 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,609 F4 · price: This transaction was executed in multiple trades at prices ranging from $73.56 to $74.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,670 | $73.22 | $195,489.39 |
DisclosureSEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 3 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,812 F3 · price: This transaction was executed in multiple trades at prices ranging from $72.56 to $73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 22,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,482 F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 35,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,684 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,090 | $86.91 | $181,650.47 |
DisclosureSEC source: 0001093557-25-000019 · wk-form4_1738280669.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,526 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 47,625 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000019 · wk-form4_1738280669.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,616 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F2 · balance_after: Included in this number are 47,625 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 744 | $76.87 | $57,191.28 |
DisclosureSEC source: 0001093557-24-000191 · wk-form4_1734470133.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,030 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 47,625 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 21:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,500 | $75.51 | $264,285.00 |
DisclosureSEC source: 0001093557-24-000182 · wk-form4_1731964314.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,774 F1 · shares: On November 21, 2023, Mr. Sylvain adopted a 10b5-1 Plan which was amended on August 6, 2024. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 49,085 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 1,460 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:05 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 746 | $69.15 | $51,585.90 |
DisclosureSEC source: 0001093557-24-000168 · wk-form4_1726095904.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,274 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 49,085 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,460 of which were granted on December 15, 2021 and shall vest through December 15, 2024, and 72 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 22:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 745 | $115.05 | $85,712.85 |
DisclosureSEC source: 0001093557-24-000129 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,948 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 50,549 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,924 of which were granted on December 15, 2021 and shall vest through December 15, 2024 and 159 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 11,661 | $134.41 | $1,567,363.17 |
DisclosureSEC source: 0001093557-24-000054 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,534 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 52,009 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,384 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:32 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 26,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000040 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,195 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 52,009 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,384 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,363 | $116.73 | $392,562.99 |
DisclosureSEC source: 0001093557-24-000026 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,142 F1 · shares: On November 21, 2023, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 48,809 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,734 | $123.63 | $338,017.54 |
DisclosureSEC source: 0001093557-24-000013 · edgardoc.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,505 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 48,809 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 7,171 | $0.00 | $7.17 |
DisclosureSEC source: 0001093557-24-000013 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,239 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F2 · balance_after: Included in this number are 48,809 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:36 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,932 | $121.85 | $357,260.97 |
DisclosureSEC source: 0001093557-23-000253 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,068 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 48,809 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| August 22, 2023 Filed Aug 22, 2023 20:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,844 | $104.38 | $192,476.72 |
DisclosureSEC source: 0001093557-23-000181 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,867 F1 · shares: On August 22, 2022, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| May 22, 2023 Filed May 23, 2023 23:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,400 | $117.58 | $282,192.00 |
DisclosureSEC source: 0001093557-23-000146 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,711 F1 · shares: On August 22, 2022, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:53 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 783 | $111.40 | $87,225.42 |
DisclosureSEC source: 0001093557-23-000085 · edgardoc.xml · nonDerivative · entry 4 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,111 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:53 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,857 | $111.40 | $206,867.94 |
DisclosureSEC source: 0001093557-23-000085 · edgardoc.xml · nonDerivative · entry 3 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,894 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:53 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,604 | $111.40 | $401,482.00 |
DisclosureSEC source: 0001093557-23-000085 · edgardoc.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,751 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:53 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,374 | $111.40 | $375,860.23 |
DisclosureSEC source: 0001093557-23-000085 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,355 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 20:57 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 21,769 | $0.00 | $21.77 |
DisclosureSEC source: 0001093557-23-000049 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,729 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| February 22, 2023 Filed Feb 22, 2023 23:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,400 | $114.54 | $274,896.00 |
DisclosureSEC source: 0001093557-23-000026 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,837 F1 · shares: On August 22, 2022, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 54,332 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,400 | $112.62 | $270,288.00 |
DisclosureSEC source: 0001093557-22-000179 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,237 F1 · shares: On August 22, 2022, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 54,332 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| June 06, 2022 Filed Jun 6, 2022 20:52 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $301.57 | $180,942.00 |
DisclosureSEC source: 0001093557-22-000128 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,408 F1 · shares: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 192 | $406.06 | $77,962.89 |
DisclosureSEC source: 0001093557-22-000057 · edgardoc.xml · nonDerivative · entry 5 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,008 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 424 | $406.06 | $172,168.04 |
DisclosureSEC source: 0001093557-22-000057 · edgardoc.xml · nonDerivative · entry 4 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 844 | $406.06 | $342,711.85 |
DisclosureSEC source: 0001093557-22-000057 · edgardoc.xml · nonDerivative · entry 3 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,624 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 491 | $406.06 | $199,373.84 |
DisclosureSEC source: 0001093557-22-000057 · edgardoc.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,468 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:31 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,297 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-22-000057 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,959 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 04, 2022 Filed Mar 5, 2022 00:02 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $422.94 | $253,764.00 |
DisclosureSEC source: 0001093557-22-000025 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,662 F1 · shares: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 2,925 | $0.00 | $2.93 |
DisclosureSEC source: 0001093557-21-000291 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,217 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock. F2 · balance_after: Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 00:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $517.59 | $310,554.00 |
DisclosureSEC source: 0001093557-21-000272 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,292 F1 · shares: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 9,759 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| November 09, 2021 Filed Nov 11, 2021 00:10 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 634 | $634.12 | $402,032.08 |
DisclosureSEC source: 0001093557-21-000254 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,892 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 9,759 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5 | $541.76 | $2,708.80 |
DisclosureSEC source: 0001093557-21-000220 · edgardoc.xml · nonDerivative · entry 2 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,526 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,033 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 402 | $541.36 | $217,626.72 |
DisclosureSEC source: 0001093557-21-000220 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,531 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,033 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 22:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 587 | $545.41 | $320,155.67 |
DisclosureSEC source: 0001093557-21-000200 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,933 F1 · shares: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $346.74 | $208,044.00 |
DisclosureSEC source: 0001093557-21-000153 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,508 F1 · shares: On May 26, 2020, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 941 | $362.92 | $341,504.90 |
DisclosureSEC source: 0001093557-21-000079 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,108 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.